secwatch.observer — SEC 8-K summary
======================================

Issuer:     INTERPACE BIOSCIENCES, INC. (IDXG)
CIK:        0001054102
Form:       8-K
Filed at:   2022-01-27T23:59:59+00:00
Accession:  0001493152-22-002401
Event type: leadership
Sentiment:  neutral
Materiality: 0.20
Item codes: 1.01, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Interpace appoints Vijay Aggarwal to Board, replacing Eric Lev effective Feb 1, 2022
--------------------------------------------------------------------------------

- Eric B. Lev resigns as director effective Feb 1, 2022; no disagreement with the Company.
- Vijay Aggarwal appointed to Board effective Feb 1, 2022 as Class I director.
- Aggarwal will Chair Regulatory Compliance Committee and serve on Nominating & Corporate Governance Committee.
- Compensation: $50k annual director fee ($40k base + $10k committee chair) plus option for 28k shares.
- Aggarwal has 30+ years in diagnostics/pharma; previously CEO of Vaxigenix, President of Aureon Labs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1054102/000149315222002401/0001493152-22-002401-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1054102/000149315222002401/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-002401

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer